Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Jan 06, 2024 7:16pm
134 Views
Post# 35814150

RE:RE:RE:RE:RE:RE:RE:Back to our regularly scheduled program

RE:RE:RE:RE:RE:RE:RE:Back to our regularly scheduled program

More math trickery from the HOBBS leader 

here's just some of the ways where he went wrong in his analysis :

1. conveniently selects the slow period before the Investigator meeting in May when Tigris got a major shot in the arm  

2. conveniently leaves out the fact that a new CRO was put in place in the summer of 2023

3. conveniently leaves out the fact that several new hospitals have been brought on board in the last six months resulting in an improved the pace of enrollment. ( also noting that a few more are due to be announced) . 
 

extrapolations only work when the parameters/ underlying factors remain unchanged. Clearly they are not the same... despite what the  HOBBS Leader would have you believe. 



And of course as BJ points out,  he completely misses the fact that there will be investor excitement and anticipation around the key milestone of 90 patients which could be achieved within weeks. Regardless of an early stoppage or not, or a buyout decision or not, or anticipated funding injection by the billion $ partner. 


MM 

<< Previous
Bullboard Posts
Next >>